Clinical Trials | Page 15 | Aplastic Anemia and MDS International Foundation

Clinical Trials

Clinical research is at the heart of all medical advances, identifying new ways to prevent, detect or treat disease. If you have a bone marrow failure disease, you may want to consider taking part in a clinical trial, also called a research study.

LY2606368 in Combination With Cytarabine and Fludarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS)

Status(es): Not yet recruiting
Study Date(s): Saturday, April 30, 2016 to Thursday, April 1, 2021
Disease(s): myelodysplastic syndromes (MDS)
Age Group: 18 years and older
The goal of this clinical research study is to study the safety of LY2606368 when given in combination with fludarabine and cytarabine. The effectiveness of the study drug combination when given to patients with relapsed or refractory AML or HRMDS will also be studied.

Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse

Status(es): Recruiting
Study Date(s): Sunday, December 1, 2013 to Wednesday, November 1, 2017
Disease(s): myelodysplastic syndromes (MDS)
Age Group: 1 year to 75 years
The purpose of this study is to learn if 5'-Azacitidine will help to lower the risk of the disease coming back after a stem cell transplant in patients with MDS and AML. This study will also be looking at the side effects of this medicine. 5'-Azacitidine is an FDA approved drug for treatment of MDS and AML, as well as patients whose disease came back after transplant, where it helped going into remission. It is unclear if 5'-Azacitidine can prevent the disease from coming back after transplant. This study will help show if getting 5'-Azacitidine soon after transplant can lower the risk of...

Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients

Status(es): Recruiting
Study Date(s): Sunday, May 15, 2016 to Saturday, August 1, 2020
Disease(s): myelodysplastic syndromes (MDS)
Age Group:
Allogeneic transplant can sometimes be an effective treatment for leukemia. In a traditional allogeneic transplant, patients receive very high doses of chemotherapy and/or radiation therapy, followed by an infusion of their donor's bone marrow or blood stem cells. The high-dose chemotherapy drugs and radiation are given to remove the leukemia cells in the body. The infusion of the donor's bone marrow or blood stem cells is given to replace the diseased bone marrow destroyed by the chemotherapy and/or radiation therapy. However, there are risks associated with allogeneic transplant. Many...

Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia

Status(es): Recruiting
Study Date(s): Wednesday, July 1, 2009 to Friday, July 1, 2016
Disease(s): myelodysplastic syndromes (MDS)
Age Group:
RATIONALE: Midostaurin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Midostaurin may help azacitidine kill more cancer cells by making the cancer cells more sensitive to the dru

Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant

Status(es): Recruiting
Study Date(s): Sunday, November 1, 2015 to Wednesday, November 1, 2017
Disease(s): myelodysplastic syndromes (MDS)
Age Group: 18 years to 75 years
This randomized phase II trial studies the safety and how well multi-peptide cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) vaccine works in reducing CMV complications in patients previously infected with CMV and are undergoing a donor hematopoietic cell transplant. CMV is a virus that may reproduce and cause disease and even death in patients with lowered immune systems, such as those undergoing a hematopoietic cell transplant. By placing 3 small pieces of CMV deoxyribonucleic acid (DNA) (the chemical form of genes) into a very safe, weakened virus called MVA, the multi-peptide CMV-...

Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant

Status(es): Recruiting
Study Date(s): Monday, June 6, 2016
Disease(s): myelodysplastic syndromes (MDS)
Age Group: 18 years to 60 years
The main purpose of this trial is to assess the efficacy and safety of sitagliptin in enhancing engraftment following umbilical cord blood transplantation (recovery of blood counts after transplant).

Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant

Status(es): Recruiting
Study Date(s): Thursday, November 1, 2012 to Sunday, November 1, 2015
Disease(s): myelodysplastic syndromes (MDS)
Age Group: 18 to 80
The main purpose of this trial is to assess the efficacy and safety of sitagliptin in enhancing engraftment following umbilical cord blood transplantation (recovery of blood counts after transplant).

Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies

Status(es): Recruiting
Study Date(s): Saturday, March 1, 2008 to Wednesday, January 1, 2020
Disease(s): myelodysplastic syndromes (MDS)
Age Group: up to 21 years
The purpose of this study is to show that myeloablative hematopoietic progenitor cell transplantation (HPCT) continues to offer acceptable disease-free survival for select patients requiring HPCT.

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

Status(es): Recruiting
Study Date(s): Friday, July 1, 2005 to Saturday, October 1, 2016
Disease(s): myelodysplastic syndromes (MDS)
Age Group: up to 55 years
Giving chemotherapy drugs, such as fludarabine and cyclophosphamide, and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells and prepares the patient's bone marrow for the stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil may stop this...

Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies

Status(es): Recruiting
Study Date(s): Saturday, September 1, 2012 to Thursday, September 1, 2016
Disease(s): myelodysplastic syndromes (MDS)
Age Group: 2 years to 70 years
The purpose of this study is to find out whether the addition of blood stem cells from a close family member, when added to two units of umbilical cord blood will make the transplant safer.